EntryPoint Capital LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

EntryPoint Capital LLC acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the fourth quarter, Holdings Channel reports. The fund acquired 32,425 shares of the company’s stock, valued at approximately $378,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Whipplewood Advisors LLC acquired a new stake in Intellia Therapeutics during the fourth quarter worth approximately $40,000. Jones Financial Companies Lllp grew its holdings in shares of Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock valued at $60,000 after purchasing an additional 2,299 shares in the last quarter. KBC Group NV lifted its position in Intellia Therapeutics by 62.4% during the fourth quarter. KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after purchasing an additional 2,340 shares during the period. Finally, Point72 DIFC Ltd acquired a new stake in Intellia Therapeutics during the third quarter worth about $151,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 29,000 shares of company stock worth $352,551 over the last ninety days. Insiders own 3.20% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the subject of several analyst reports. Chardan Capital dropped their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Citigroup raised their target price on Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Wedbush reiterated a “neutral” rating and issued a $10.00 price target (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Oppenheimer reduced their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. Finally, BMO Capital Markets lowered their target price on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Trading Down 4.8 %

NASDAQ NTLA opened at $8.31 on Thursday. The firm has a market capitalization of $860.23 million, a PE ratio of -1.53 and a beta of 1.97. The business’s 50-day moving average price is $10.03 and its two-hundred day moving average price is $13.93. Intellia Therapeutics, Inc. has a 12 month low of $8.12 and a 12 month high of $28.23.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.